Uncategorized The biosimilar race in China

The biosimilar race in China

Across the globe, many countries have pegged big hopes on biosimilars. The situation is no different in China.  In the face of the supportive pharmaceutical industry policies, the biosimilar drug development in China is riding on an upward trend. However, compared to the advanced US and European market, China still has plenty of room to …

Read Article Read More

Uncategorized China’s CAR-T Therapy Race

China’s CAR-T Therapy Race

On March 12, 2018 the Chinese FDA (CFDA) approved the clinical trial application of LCAR-B38M CAR-T cell self-reinfusion preparation from Nanjing Legend Biotech, marking the first cellular therapy to officially enter the clinical trial stage in China. LCAR-B38M is targeted at B-cell maturation antigen (BCMA), a member of TNF receptor family and also an extremely …

Read Article Read More